EAU-EANM-ESTRO-ESUR-ISUP-SIOG 前列腺癌指南 2026 更新第一部分:筛查、诊断与根治性局部治疗
该指南 2026 版由 EAU 联合 EANM、ESTRO、ESUR、ISUP、SIOG 制定,基于 2023 年 5 月至 2025 年文献更新,涵盖临床局限性前列腺癌筛查、诊断与根治性局部治疗,并新增推荐强度分级。核心推荐包括风险适应筛查策略、多参数磁共振避免不必要穿刺、靶向联合区域穿刺、新五级 EAU 分类、PSMA PET 用于转移检测、低危及选择性有利中危 ISUP 2 级行主动监测。
要点
- 风险适应筛查一般从 50 岁开始,结合个体预期寿命决定。
- 推荐多参数磁共振以减少不必要穿刺,穿刺时行靶向联合区域穿刺。
- 低危及选择性有利中危 ISUP 2 级推荐主动监测。
核心结论
- 临床局限性前列腺癌诊断、分期与治疗证据快速演变,指南体现多学科管理。
研究设计与样本
- EAU 联合 EANM、ESTRO、ESUR、ISUP、SIOG 制定指南,检索 2023 年 5 月至 2025 年英文新数据并更新推荐强度。
主要发现
- 建议采用风险适应策略识别可能发生前列腺癌的男性,一般从 50 岁开始并基于个体预期寿命。
- 推荐使用多参数磁共振成像以避免不必要穿刺。
- 考虑穿刺时,应行靶向穿刺联合区域穿刺。
- 引入新的五级 EAU 分类。
- 前列腺特异性膜抗原正电子发射断层成像(PSMA PET)是识别转移扩散最敏感的技术。
关键数值与推荐
- 风险适应筛查一般从 50 岁开始,基于个体预期寿命。
- 低危前列腺癌及选择性有利中危 ISUP 等级分组 2 病变适合主动监测。
- 中危患者考虑大分割放疗。
- cN1 患者推荐原发肿瘤放疗联合长期强化激素治疗。
临床怎么用
- 临床可按风险适应策略从 50 岁起结合预期寿命进行筛查。
- 用多参数磁共振减少不必要穿刺,穿刺时采用靶向联合区域穿刺。
- 按新五级 EAU 分类分层,低危及选择性有利中危 ISUP 2 级行主动监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: To present a summary of the 2026 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and treatment of clinically localised prostate cancer (PCa). METHODS: The Panel performed a literature review of all new data published in English, covering the time frame between May 2023 and 2025. The Guidelines were updated, and a strength rating for each recommendation was added based on a systematic review of the evidence. KEY FINDINGS: A risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. The use of multiparametric magnetic resonance imaging to avoid unnecessary biopsies is recommended. When a biopsy is considered, a combination of targeted and regional biopsies should be performed. A new five-tier EAU classification has been introduced. Prostate-specific membrane antigen positron emission tomography imaging is the most sensitive technique for identifying metastatic spread. Active surveillance is the appropriate management for men with low-risk PCa, as well as for patients with selected favourable intermediate-risk ISUP grade group 2 lesions. Local therapies are addressed, as well as the management of persistent prostate-specific antigen after surgery. A recommendation to consider hypofractionated radiotherapy in intermediate-risk patients is provided. Patients with cN1 PCa should be offered radiotherapy to the primary tumour combined with long-term intensified hormonal treatment. CONCLUSIONS AND CLINICAL IMPLICATIONS: The evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. These PCa Guidelines reflect the multidisciplinary nature of PCa management.
引用
- Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2026. PMID: 42457454. doi:10.1016/j.eururo.2026.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。